|Bid||0.00 x 20000|
|Ask||0.00 x 9000|
|Day's range||152.00 - 154.50|
|52-week range||135.50 - 172.95|
|PE ratio (TTM)||13.96|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
This week the cancer space was abuzz with news of label expansion of Kyprolis, Lynparza and Kymriah and positive data readouts for Cabometyx and Keytruda.
The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis
AbbVie’s (ABBV) market-leading immunology drug, Humira (adalimumab), reported worldwide revenues of $4.7 billion in 3Q17.
If you’d invested in the average S&P 500 stock back in 1970, you’d be yielding 55.8% on your original buy today. Think about that: 55.8% is more than half of what you originally invested—returned to your pocket every year in dividend checks!
Amgen Inc (AMGN.O) said it expects to incur tax expenses of $6 billion to $6.5 billion over time as it repatriates cash it has accumulated around the world because of the new U.S. tax law signed by President Donald Trump on Friday. Some of the expense is also due to the revaluation of its tax liabilities, the drugmaker said in a filing with the Securities and Exchange Commission. Amgen did not say how much of its $38.9 billion in cash and other holdings it plans to move back to the United States.
Gilead Sciences (GILD), a leading biopharmaceutical company headquartered in California, is involved in discovering, developing, and commercializing various innovative medicines.
Goldman Sachs is out with an update on healthcare ahead of the new year, and while analyst Jami Rubin and her team still bullish on Amgen (AMGN), she removed it from the firm's Conviction Buy list. Rubin still reiterated a Buy rating on the stock and $218 price target, writing that she believes new products will offset erosion of its legacy biologics, like Neulasta, which is facing increasing competition, and continue to drive low-single-digit growth.
Biotech giant Amgen (AMGN) is providing some holiday cheer to investors with a 15% dividend increase. Last year Amgen paid out about one-third of its earnings in dividends. Shares of Amgen have gained 0.3% to $176.79 at 12:20 p.m. today, while the iShares Nasdaq Biotechnology ETF (IBB) has risen 0.3% to $106.09.
23 analysts were tracking Pfizer in November 2017. One analyst recommended a “strong buy,” while 11 analysts recommended a “buy.”
23 analysts were tracking Bristol-Myers Squibb in November 2017. Six of them recommended a “strong buy” rating, while four recommended a “buy.”
After Puerto Rico’s ailing economy was crippled by Hurricane Maria, the island’s leaders fear that the Republican tax overhaul could deliver another devastating blow.
In November 2017, the FDA approved Merck’s (MRK) Prevymis (letermovir) for the prevention of CMV (cytomegalovirus) infection and disease in adult CMV-seropositive recipients of allogeneic hematopoietic ...
GE isn’t the only household name I’m worried about. There is another popular dividend stock showing some very similar signs.
AstraZeneca has achieved another milestone in rebuilding its drug portfolio with U.S. approval of a drug for severe asthma as the company battles to put patent losses on older medicines behind it. The U.S. Food and Drug Administration's (FDA) decision to endorse benralizumab, which will be marketed under the name Fasenra, follows a positive recommendation for the product in Europe on Friday. Shares (Berlin: DI6.BE - news) in AstraZeneca were 1 percent higher on Wednesday following the overnight news.
In 3Q17, Novartis’s Cosentyx generated revenues of $556 million, which reflected a whopping 85% growth YoY (year-over-year) and ~13% growth QoQ.
Of the 31 analysts tracking Celgene (CELG) in November 2017, 11 analysts recommended a “strong buy” while eight analysts recommended a “buy.”
Let’s talk about the only “market timing” strategy that actually works in practice – buying a stock before it announces a dividend hike.